NLS Pharmaceutics Secures Patent for Dual Orexin Receptor Agonists
The new patent application from Aexon Labs, licensed to NLS Pharmaceutics, covers dual orexin receptor agonists designed to treat narcolepsy.
Source: sleepreviewmag.com
Aexon Labs News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Aexon Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Aexon Labs Today - Breaking & Trending Today
NLS Pharmaceutics CEO Issues Letter to Shareholders
ZURICH, SWITZERLAND / ACCESSWIRE / December 29, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
Source: pharmiweb.com
NLS Pharmaceutics, Whose Narcolepsy Drug Candidate Is In Clinical Trials, Recaps 2023
In a letter to shareholders, the CEO of NLS Pharmaceutics Ltd recapped the company’s progress and pitfalls for 2023.
Source: sleepreviewmag.com
Press release titled: "NLS Pharmaceutics CEO Issues Letter to Shareholders." - Form 6-K -December 29, 2023 at 04:39 pm EST
Zürich, Switzerland, December 29, 2023 - NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for...
Source: marketscreener.com
NLS Pharmaceutics : UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS - Form 6-K -December 06, 2023 at 04:49 pm EST
UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page ...
Source: marketscreener.com